Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy — FSHD

Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial

Official title:
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy

Status Completed

Clinical Trial Summary

The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with early onset FSHD.

Clinical Trial Description

A Phase 1b/2 open-label, intraparticipant dose-escalation study aiming to evaluate the safety, tolerability, immunogenicity, biological and pharmacodynamic activity of intravenous ATYR1940, administered once weekly for 12 weeks, in early onset FSHD participants with signs or symptoms prior to 10 years of age. ;

Study Design

Related Conditions & MeSH terms

Facioscapulohumeral Muscular Dystrophy (FSHD)
Muscular Dystrophies
Muscular Dystrophy, Facioscapulohumeral

Clinical Trial Details

NCT number	NCT02603562
Study type	Interventional
Source	aTyr Pharma, Inc.
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	March 30, 2016
Completion date	December 12, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02239224` - Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy	Phase 1/Phase 2
Active, not recruiting	`NCT05397470` - Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)	Phase 3
Active, not recruiting	`NCT05548556` - A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy	Phase 2
Active, not recruiting	`NCT04264442` - Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)	Phase 2
Completed	`NCT04003974` - Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)	Phase 2